menu

Testing and Screening for Type 1 Diabetes (T1D): Genes, Antigens, Autoantibodies, Methodology and Clinical Utility

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Testing and Screening for Type 1 Diabetes (T1D): Genes, Antigens, Autoantibodies, Methodology and Clinical Utility

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Autoantibody Screening to Identify Risk for Type 1 Diabetes
    T1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.

  • Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Mark A. Atkinson, PhD – Has no relevant financial relationship(s) with ineligible companies to disclose

    Linda DiMeglio, MD, MPH – Consultant/Advisor/Speaker: Merck, Vertex, Provention, Abata; DSMB Member: Eli Lilly

    Stephen Gitelman, MD – Consultant/Advisor/Speaker: Rubius Therapeutics, Avotres, Sana Biotechnology, Abata Therapeutics, Provention Bio; Researcher: Provention Bio; DSMB: Diamyd; Individually publicly traded stocks and stock options: SAB Biotherapeutics

    Emily Sims, MD - Has no relevant financial relationship(s) with ineligible companies to disclose

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The HealthmattersCME planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

  • Target Audience

    This activity is intended for physicians, PAs, NPs, nurses and other healthcare providers who care for patients with Type 1 Diabetes.

  • Learning Objectives

    Upon completion of these activities, participants should be able to:

    • Incorporate into practice how increased knowledge and awareness of T1D genetics and islet-cell autoantibodies can be used to predict and diagnose TID
    • Apply into practice the potential long-term benefits of preclinical diagnosis of T1D by autoantibody screening
    • Request T1D screening of children at increased risk when they are at an optimal age for pancreatic β cell autoantibody assays
    • Integrate screening for T1D into practice to potentially delay or prevent progression from islet autoimmunity to T1D, reduce the risk of clinical presentation as diabetic ketoacidosis, and attenuate the severity of T1D complications
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and HealthmattersCME.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Education
    PACE designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is .5 contact hours.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Instructions

    In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of each activity.

    For additional information about the accreditation of this activity, please visit https://partnersed.com

  • Provider(s)/Educational Partner(s)

    Jointly provided by Partners for Advancing Clinical Education (PACE) and HealthmattersCME.

  • Commercial Support

    This activity is supported by an independent educational grant from Provention Bio.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Autoantibody Screening to Identify Risk for Type 1 Diabetes
    T1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.

  • Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Mark A. Atkinson, PhD – Has no relevant financial relationship(s) with ineligible companies to disclose

    Linda DiMeglio, MD, MPH – Consultant/Advisor/Speaker: Merck, Vertex, Provention, Abata; DSMB Member: Eli Lilly

    Stephen Gitelman, MD – Consultant/Advisor/Speaker: Rubius Therapeutics, Avotres, Sana Biotechnology, Abata Therapeutics, Provention Bio; Researcher: Provention Bio; DSMB: Diamyd; Individually publicly traded stocks and stock options: SAB Biotherapeutics

    Emily Sims, MD - Has no relevant financial relationship(s) with ineligible companies to disclose

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The HealthmattersCME planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

  • Target Audience

    This activity is intended for physicians, PAs, NPs, nurses and other healthcare providers who care for patients with Type 1 Diabetes.

  • Learning Objectives

    Upon completion of these activities, participants should be able to:

    • Incorporate into practice how increased knowledge and awareness of T1D genetics and islet-cell autoantibodies can be used to predict and diagnose TID
    • Apply into practice the potential long-term benefits of preclinical diagnosis of T1D by autoantibody screening
    • Request T1D screening of children at increased risk when they are at an optimal age for pancreatic β cell autoantibody assays
    • Integrate screening for T1D into practice to potentially delay or prevent progression from islet autoimmunity to T1D, reduce the risk of clinical presentation as diabetic ketoacidosis, and attenuate the severity of T1D complications
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and HealthmattersCME.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Education
    PACE designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is .5 contact hours.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Instructions

    In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of each activity.

    For additional information about the accreditation of this activity, please visit https://partnersed.com

  • Provider(s)/Educational Partner(s)

    Jointly provided by Partners for Advancing Clinical Education (PACE) and HealthmattersCME.

  • Commercial Support

    This activity is supported by an independent educational grant from Provention Bio.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule31 Jan 2023